Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.

Neurologia medico-chirurgica - 1 Aug 2007

Ishii Dai, Natsume Atsushi, Wakabayashi Toshihiko, Hatano Hisashi, Asano Yoshio, Takeuchi Hiroki, Shimato Shinji, Ito Motokazu, Fujii Masazumi, Yoshida Jun

Abstract excerpt

Promoter methylation of the deoxyribonucleic acid (DNA) repair gene, O(6)-methylguanine-DNA methyltransferase (MGMT), is associated with improved outcome of patients with glioblastoma multiforme and anaplastic astrocytoma treated with temozolomide (TMZ). Molecular genetic analysis of loss of heterozygosity (LOH) of 1p, 19q, or 10q, p53 mutation, and MGMT promoter methylation was performed in 44 assessable tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Chromosomes, Human, Pair 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 19

Share to Dacarbazine

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioma

Share to Temozolomide

Source

Identifiers

PMID: 17721049
DOI: 10.2176/nmc.47.341

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.PMID 17721049Read ↗

Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO StudySemantic proximity Read ↗

Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions.Semantic proximity Read ↗

Frequent promoter hypermethylation and low expression of the <i>MGMT</i> gene in oligodendroglial tumorsSemantic proximity Read ↗

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Semantic proximity Read ↗

MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaSemantic proximity Read ↗

The role of MGMT testing in clinical practice: a report of the association for molecular pathology.Semantic proximity Read ↗

Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.Semantic proximity Read ↗

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.Semantic proximity Read ↗

The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.Semantic proximity Read ↗

Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumorsSemantic proximity Read ↗

Correlation of chromosomes 1p and 19q status and expressions of O<sup>6</sup>‐methylguanine DNA methyltransferase (MGMT), p53 and Ki‐67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological studySemantic proximity Read ↗

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.